GLENMARK PHARMACEUTICALS
|
|
BOM : 532296     NSE : GLENMARK     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Good [Stock is Cheap] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Feb 06,2023 |
Price(EOD): ₹ 399.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 11,265.42 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
GLENMARK PHARMACEUTICALS | 3.9% | -8% | -23.3% |
SUN PHARMACEUTICAL INDUSTRIES | -1.1% | 0.8% | 15.6% |
DIVIS LABORATORIES | -16.3% | -19.7% | -31.6% |
CIPLA | 1.3% | -5.4% | 7.5% |
DR REDDYS LABORATORIES | 0.6% | 1.3% | -1.3% |
TORRENT PHARMACEUTICALS | 1.2% | -1.3% | 12% |
ABBOTT INDIA | 0.2% | -5.5% | 28.7% |
ZYDUS LIFESCIENCES | 9.2% | 8.7% | 4.7% |
ALKEM LABORATORIES | 2% | 0.9% | -14% |
FUNDAMENTAL ANALYSIS OF GLENMARK PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GLENMARK PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
12.49
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 902.10 Cr
[Latest Qtr - Sep2022 - Consolidated Results ] 1.24
P/B Calculated based on Book Value of Rs 9,070.35 Cr
[Latest Year - Mar2022 - Consolidated Results ] 0.91
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 12,345.10 Cr
[Latest Qtr - Sep2022 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-64% -69% -66% |
SHARE PRICE MOMENTUM OF GLENMARK PHARMACEUTICALS
GLENMARK PHARMACEUTICALS vs SENSEX
DEBT OF GLENMARK PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.22 0.25 0.27 0.25 |
0.4 0.67 0.8 0.62 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF GLENMARK PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF GLENMARK PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
21.53% 44.01% 17.7% 32% |
7.24% 5.32% 24.74% 1.41% |
QtrlyTrend |
8 | |
Latest Qtr: Sep2022 | ||
Quarterly Result Analysis → |
GLENMARK PHARMACEUTICALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 250 SMALLCAP | 2% | -2.7% | -5.1% |
S&P BSE 400 MIDSMALLCAP | 1.8% | -2.2% | -1.7% |
S&P BSE MIDSMALLCAP | 1.5% | -3% | -3.2% |
S&P BSE MID CAP | 1.4% | -2.5% | -1% |
S&P BSE 500 | 0.5% | -3% | -1.1% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY FREE SMALL 100 | 2.5% | -2.7% | -15.3% |
NIFTY SMALLCAP250 | 1.8% | -3.1% | -7.1% |
NIFTY MID SMALL400 | 1.7% | -2.6% | -1.8% |
NIFTY500 MULTICAP 50:25:25 | 1% | -2.9% | -2.1% |
NIFTY 500 | 0.5% | -3% | -1.2% |
You may also like the below Video Courses
FAQ about GLENMARK PHARMACEUTICALS
Is GLENMARK PHARMACEUTICALS good for long term investment?
As on Feb 06,2023, the Fundamentals of GLENMARK PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of GLENMARK PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GLENMARK PHARMACEUTICALS UnderValued or OverValued?
As on Feb 06,2023, GLENMARK PHARMACEUTICALS is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GLENMARK PHARMACEUTICALS ?
As on Feb 06,2023, the Intrinsic Value of GLENMARK PHARMACEUTICALS is Rs. 1,178.01 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,110.48
Fair Value [Median EV / Sales Model] : Rs. 1,296.05
Fair Value [Median Price / Sales Model] : Rs. 1,178.01
Estimated Median Fair Value of GLENMARK PHARMACEUTICALS : Rs. 1,178.01
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is GLENMARK PHARMACEUTICALS trading at a Premium or Discount?
As on Feb 06,2023, GLENMARK PHARMACEUTICALS is trading at a Discount of -66% based on the estimates of Median Intrinsic Value!